Meeting Report
Biomarker Jeopardy
Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Haleigh Mistry,(3) MS, PA-C
From (1)The University of Arizona Cancer Center, Phoenix, Arizona; (2)HonorHealth – Virginia G. Piper Cancer Care Network, Scottsdale, Arizona; (3)The University of Texas MD Anderson Cancer Center, Houston, Texas
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(3):292–297 |
https://doi.org/10.6004/jadpro.2022.13.3.22 |
© 2022 Harborside™
ABSTRACT
In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker testing.
For access to the full length article, please
sign in.
